Vestal Point Capital’s AstraZeneca AZN Stock Holding History

Vestal Point Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85.3M	Buy	450,000 +350,000	+350%	+$65.8M	1.99%	16
2026 Q1	$19.7M	Buy	+100,000	New	+$19.3M	0.55%	50
2025 Q1	–	Sell	-237,500	Closed	-$31.1M	–	66
2024 Q4	$31.1M	Buy	+237,500	New	+$33.3M	1.85%	23
2024 Q2	–	Sell	-200,000	Closed	-$27.1M	–	65
2024 Q1	$27.1M	Buy	200,000 +75,000	+60%	+$9.93M	2.24%	13
2023 Q4	$16.8M	Buy	+125,000	New	+$16.2M	1.78%	19

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vestal Point Capital's AZN Position: Q2 2026 in Review

Vestal Point Capital increased its AstraZeneca (AZN) stake by 350% in Q2 2026, buying an estimated $65.8M and bringing the position to 450,000 shares worth $85.3M. The position accounts for 1.99% of the portfolio, ranked #16.

Vestal Point Capital first reported a position in AZN in Q4 2023 and has held it in 5 quarters since. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Vestal Point Capital held 450,000 shares of AstraZeneca worth $85.3M as of Q2 2026.
Vestal Point Capital bought 350,000 AstraZeneca shares in Q2 2026, an estimated $65.8M.
AstraZeneca made up 1.99% of Vestal Point Capital's portfolio in Q2 2026, its #16 holding.
Vestal Point Capital first reported a position in AstraZeneca in Q4 2023 and has held it in 5 quarters since.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.